Free Trial
NYSE:STE

STERIS (STE) Stock Price, News & Analysis

$239.82
+0.77 (+0.32%)
(As of 09/6/2024 ET)
Today's Range
$237.66
â–Ľ
$242.03
50-Day Range
$213.47
â–Ľ
$243.37
52-Week Range
$195.47
â–Ľ
$245.81
Volume
365,096 shs
Average Volume
351,923 shs
Market Capitalization
$23.65 billion
P/E Ratio
62.78
Dividend Yield
0.87%
Price Target
$246.00

STERIS MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
2.6% Upside
$246.00 Price Target
Short Interest
Healthy
2.63% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
0.58mentions of STERIS in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$113,369 Sold Last Quarter
Proj. Earnings Growth
9.28%
From $9.05 to $9.89 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

103rd out of 910 stocks

Surgical Appliances & Supplies Industry

7th out of 18 stocks

STE stock logo

About STERIS Stock (NYSE:STE)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

STE Stock Price History

STE Stock News Headlines

Brokers Offer Predictions for STERIS plc's Q2 2025 Earnings (NYSE:STE)
The solution to fast food’s wage hike crisis
Shake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.
Steris Market Position and Outlook: A Hold Recommendation
STERIS (NYSE:STE) PT Raised to $265.00
STERIS (NYSE:STE) Sets New 12-Month High on Analyst Upgrade
The solution to fast food’s wage hike crisis
Shake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.
KeyBanc Sticks to Its Buy Rating for Steris (STE)
STERIS plc (NYSE:STE) Plans Dividend Increase - $0.57 Per Share
See More Headlines
Receive STE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STERIS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 6/26 Dividend
6/12/2024
Dividend Payable
6/26/2024
Last Earnings
8/06/2024
Ex-Dividend for 9/20 Dividend
9/05/2024
Today
9/07/2024
Dividend Payable
9/20/2024
Next Earnings (Estimated)
11/05/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
CUSIP
85915210
Employees
18,179
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$246.00
High Stock Price Target
$265.00
Low Stock Price Target
$215.00
Potential Upside/Downside
+2.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$378.24 million
Pretax Margin
13.08%

Debt

Sales & Book Value

Annual Sales
$5.14 billion
Cash Flow
$14.00 per share
Book Value
$64.60 per share

Miscellaneous

Free Float
97,726,000
Market Cap
$23.65 billion
Optionable
Optionable
Beta
0.83

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Should I Buy STERIS Stock? STE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in STERIS plc:

  • STERIS reported earnings per share of $2.58 for the quarter, beating analysts' estimates by $0.17, indicating strong financial performance.
  • The company had a return on equity of 13.73%, showcasing efficient utilization of shareholder equity to generate profits.
  • Insider activity shows recent selling of shares, which could be seen as a positive sign as insiders may have a better understanding of the company's performance.
  • Large institutional investors have been increasing their positions in STERIS, indicating confidence in the company's future growth potential.
  • STERIS recently increased its dividend payout, providing investors with a higher yield and potentially attracting income-focused investors.

Cons

Investors should be bearish about investing in STERIS plc for these reasons:

  • STERIS had a slight decrease in revenue for the quarter compared to the same period last year, which could raise concerns about the company's growth trajectory.
  • There has been recent insider selling of company shares, which might signal a lack of confidence in the stock's future performance.
  • Analysts forecast a lower EPS for the current year compared to the previous year, potentially indicating a slowdown in earnings growth.
  • While the company's dividend payout ratio is reasonable, investors should consider the sustainability of the increased dividend in the long term.
  • Wall Street analysts have mixed ratings on the stock, with some maintaining a neutral stance, suggesting uncertainty in the market's perception of STERIS's future prospects.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 26, 2024. Please send any questions or comments about these STERIS pros and cons to contact@marketbeat.com.

STE Stock Analysis - Frequently Asked Questions

How have STE shares performed this year?

STERIS's stock was trading at $219.85 at the beginning of 2024. Since then, STE shares have increased by 9.1% and is now trading at $239.82.
View the best growth stocks for 2024 here
.

How were STERIS's earnings last quarter?

STERIS plc (NYSE:STE) issued its quarterly earnings results on Tuesday, August, 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.98 by $0.16. The company's revenue for the quarter was down .4% on a year-over-year basis.
Read the conference call transcript
.

What is Walter M. Rosebrough, Jr.'s approval rating as STERIS's CEO?

196 employees have rated STERIS Chief Executive Officer Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among the company's employees.

Who are STERIS's major shareholders?

STERIS's top institutional investors include Massachusetts Financial Services Co. MA (6.52%), APG Asset Management N.V. (3.74%), Impax Asset Management Group plc (1.16%) and Principal Financial Group Inc. (1.03%). Insiders that own company stock include Michael J Tokich, John Adam Zangerle, Mohsen Sohi, Cary L Majors, Renato Tamaro, Jacqueline B Kosecoff, Karen L Burton and Cynthia L Feldmann.
View institutional ownership trends
.

How do I buy shares of STERIS?

Shares of STE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of STERIS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT) and Pfizer (PFE).

This page (NYSE:STE) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners